@article{fdi:010068902,
  title = {{D}evelopment of a sensitive and specific serological assay based on {L}uminex technology for detection of antibodies to {Z}aire {E}bola virus},
  author = {{A}youba, {A}hidjo and {T}our{\'e}, {A}. and {B}utel, {C}hristelle and {K}eita, {A}lpha {K}abinet and {B}inetruy, {F}. and {S}ow, {M}. {S}. and {F}oulongne, {V}. and {D}elaporte, {E}ric and {P}eeters, {M}artine},
  editor = {},
  language = {{ENG}},
  abstract = {{T}he recent {Z}aire {E}bola virus ({EBOV}) outbreak in {W}est {A}frica illustrates clearly the need for additional studies with humans and animals to elucidate the ecology of {E}bola viruses ({EBV}s). {I}n this study, we developed a serological assay based on the {L}uminex technology. {N}ine recombinant proteins representing different viral regions (nucleoprotein [{NP}], 40-k{D}a viral protein [{VP}40], and glycoprotein [{GP}]) from four of the five {EBV} lineages were used. {S}amples from 94 survivors of the {EBOV} outbreak in {G}uinea and negative samples from 108 patients in {F}rance were used to calculate test performance for {EBOV} detection and cross-reaction with other {E}bola virus lineages. {F}or {EBOV} antibody detection, sensitivities of 95.7%, 96.8%, and 92.5% and specificities of 94.4%, 95.4%, and 96.3% for {NP}, {GP}, and {VP}40, respectively, were observed. {A}ll {EBOV}-negative samples that presented a reaction, except for one, interacted with a single antigen, whereas almost all samples from {EBOV} survivors were simultaneously reactive with {NP} and {GP} (90/94) or with {NP}, {GP}, and {VP}40 (87/ 94). {C}onsidering as positive for past {EBOV} infection only samples that reacted with {EBOV} {NP} and {GP}, sensitivity was 95.7% and specificity increased to 99.1%. {C}omparing results with commercial {EBOV} {NP} and {GP} enzyme-linked immunosorbent assays ({ELISA}s; {A}lpha {D}iagnostic, {S}an {A}ntonio, {TX}), lower sensitivity (92.5%) and high specificity (100%) were observed with the same positivity criteria. {S}amples from {EBOV} survivors cross-reacted with {GP} from {S}udan {E}bola virus ({GP}-{SUDV}) (81.9%), {GP} from {B}undibugyo {E}bola virus ({GP}-{BDBV}) (51.1%), {GP} from {R}eston {E}bola virus ({GP}-{RESTV}) (9.6%), {VP}40-{SUDV} (76.6%), and {VP}40-{BDBV} (38.3%). {O}verall, we developed a sensitive and specific high-throughput serological assay, and defined an algorithm, for epidemiological surveys with humans.},
  keywords = {{E}bola virus ; serology ; {L}uminex ; recombinant proteins},
  booktitle = {},
  journal = {{J}ournal of {C}linical {M}icrobiology},
  volume = {55},
  numero = {1},
  pages = {165--176},
  ISSN = {0095-1137},
  year = {2017},
  DOI = {10.1128/jcm.01979-16},
  URL = {https://www.documentation.ird.fr/hor/fdi:010068902},
}